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BY-NC-ND license (http://creativecomAbstract Objective: To explore the feasibility of establishing the disease-syndrome com-
bined animal model for immune thrombocytopenic purpura (ITP) without additional condi-
tions.
Methods: Three batches of data related to the ITP model mice obtained by replication at
different time were analyzed, and whether the APS-injected model mice replicated through
the passive immune modeling method could simulate the pathogenesis and clinical character-
istics of human ITP was evaluated according to the differentiation criteria for disease-
syndrome combined model.
Results: The APS-injected replicated ITP model mice possessed the following traits: (1)
Compared with the normal group, the platelet count was significantly decreased, and coag-
ulation time was significantly increased in the model group (P < .01). (2) Compared with the
normal group, the medullary thrombocytogenous megakaryocytes were significantly
decreased (P < .05, .01, .001). (3) The APS-injected sites and other parts of the model mice
had spontaneous hemorrhage. (4) Behavioral changing signs were observed 1 week after the
modeling (i.e. low activity, delayed activity, poor appetite, skin petechia/hemorrhage and
spontaneous hemorrhage at the injected sites or other parts), and were getting more and
more severe.
Conclusion: According to the syndrome differentiation criteria for disease-syndrome com-
bined model of ITP, the APS-injected animal model of ITP replicated through the passive3.com (L. Zhang), chenxinyi0729@126.com (X. Chen).
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136 H. Lang et al.immune modeling method without additional conditions possesses the characteristics of
disease-syndrome combined model. It provides an ideal tool for the development of tradi-
tional Chinese medicine pharmacology experiment.
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Disease-syndrome combination is an important diagnosis/
treatment mode in traditional Chinese medicine (TCM),
which is characterized by stressing on differentiation of
syndromes and treatment.1 In order to explore the action
mechanism of medicinal herbs, the corresponding animal
model should generally be established for verification.
However, four diagnostic methods of TCM cannot be fully
utilized on animal models (e.g. inquiry, pulse-taking and
tongue inspection), thus the replicated animal model is
basically just a disease model without any TCM syn-
dromes.2 To solve the problem, it is necessary to prepare a
disease-syndrome or syndrome-disease model with other
interventions based on chronic disease.
We hold the opinion that there is a gap between this
model and disease occurrence and progress, for which the
following idea is raised, i.e. now that a disease model can
be replicated, it is possible to find out the TCM syndrome
similar to human disease by observing some external signs
of the model mice.3 Based on this hypothesis, we made an
overall analysis of the three batches of data related to the
ITP model mice replicated without additional intervention,
and evaluated whether the duplicated APS-injected ITP
model mice prepared with the passive immune modeling
method could simulate the occurrence and progress of
disease and also clinical manifestations in human ITP ac-
cording to the differentiation criteria for disease-syndrome
combined model of ITP.
Differentiation criteria for disease-syndrome
combined model
Identification criteria for disease model
The disease model of ITP mice must meet the following 4
criteria: (1) decrease in peripheral blood platelet count;
(2) hemorrhage at the injection site or spontaneous skin
petechial; (3) prolongation of blood coagulation time; (4)
decrease in medullary thrombocytogenous megakaryocytes.
Identification criteria for the syndrome model
According to human ITP clinical characters associated with
the behavior features of the experimental mice, and some
quantitative determination indices, the external manifes-
tations of human “failure of qi to control blood” syndrome
were converted to that of “failure of qi to control blood”
syndrome of the laboratory animals. The conversion in-
dexes included: (1) hemorrhage at the injection site andother areas or spontaneous skin petechia (dim spot), which
was the common features of the disease-syndrome; (2)
decreased activity, similar to fatigue; (3) sluggishness,
similar to limb weakness; (4) poor appetite, less intake of
food and water, and loose stools, similar to spleen qi defi-
ciency; (5) weight loss, similar to deficiency in the spleen
which fails to control muscles.
Differentiation criteria for the disease-syndrome
combined model
According to the evaluation indices for the disease-
syndrome model, the differentiation criteria for the
disease-syndrome combined model of ITP was specified as
follows: more than 3 of the above 4 indices observed in the
disease model (note: Index 1 was compulsory) associated
with any 3 of the above 5 indices.
Methods
Preparation of anti-mice-platelet serum
The anti-mice-platelet serum was prepared through the
following procedures: (1) The BALB/c mice were taken,
anesthetized with ether, and the whole blood from the
mouse heart was drawn and anti-coagulated with
EDTAeNa2. The platelet was separated, washed up and
diluted with physiological saline. (2) The separated platelet
was taken, mixed with an equivalent amount of complete
Freund’s adjuvant and incomplete Freund’s adjuvant
respectively into a water-in-oil form as the antigen. At
week 0, the antigen of complete Freund’s adjuvant was
injected into at least 4 sites on the sole, back and hypo-
dermis of the Cavia porcellus. On week 1, 2 and 4, the
antigen of incomplete Freund’s adjuvant was injected into
the above 4 sites. On week 5, the non-anticoagulatory
whole blood was drawn from the heart of the guinea-pig.
After 560 g  10 min centrifuging, the supernatant was
taken and the C. porcellus anti-mice-platelet serum (GP-
APS)was obtained, and stored in a 20C refrigerator for
later use. (3) Improvement was done by referring to the
ELISA method. The potency of anti-platelet-serum was
determined (i.e. replacing the pure product of China-made
lyophilized ELISA A protein by the antibody marked with
alkaline phosphatase-protein A enzyme). (4) The APS was
taken out from a 20C refrigerator, and placed in a 56C
water bath for 30 minutes. Absorption was carried out for
at least twice with an equal amount of BALB/c mice
erythrocyte, which was diluted into APS solution (1:4) with
physiological saline for later use.
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Healthy BALB/c mice (SPF-grade), 18e22 g, 8 weeks old,
half male and half female were enrolled in our study.
Before test, the blood was drawn via the caudal vein of 24
mice, and the peripheral platelet count was determined
through the fully-automatic blood cell counter. The 24 mice
were randomly divided into 2 groups (12 mice in each
group). In the normal group, the mice were fed in a routine
way. In the model group, on days 1, 3, 5, 7, 9, 11 and 13,
APS solution (1:4) was injected intraperitoneally at 100 mL/
20 g for modeling; on day 15, after the dynamic observation
of various indices, the mice were sacrificed, and the
specimen was collected for index determination.Determination methods for observation of indices
Main indices of observation as follows: (1) Disease model
indices: platelet count, bleeding degree, coagulation time,
and type of medullary megakaryocyte. (2) Syndrome model
indices: dynamic observation of the behavior of the model
mice and weight change.Statistical methods
The data was expressed as mean  SD ðx  sÞ. The
independent-sample t-test and one-way ANOVA were made
through the SPSS software. P < .05 indicated a statistical
significance.Figure 1 The first experiment showed bleeding in the
abdomen and limbs.Results
Change of the observation indices in the disease
model
Platelet count
After the experiment, 80 mL blood was drawn from the
caudal vein and it was put into an anticoagulation tube with
EDTAeNa2. After they were mixed well, blood count was
determined by automatic cell counter. The results of
platelet count of three test batches are shown in Table 1.
As shown in Table 1, after the modeling, the peripheral
blood platelet count of model mice dropped obviously,
which was statistically significant compared with those in
the normal group of the same test batch (P < .01).Table 1 Change in platelet count ðx  sÞ.
Test batch Platelet count (109/L)
Normal group (n) Control group (n)
1st test
batch
967.00  301.30 (12) 618.1  192.10* (11)
2nd test
batch
542.80  116.13 (10) 313.60  77.69* (10)
3rd test
batch
552.00  114.00 (9) 314.00  78.00* (10)
Note: *P < .01, as compared with that in the normal group.Hemorrhage degree
As shown in Figs. 1e3, in the continuous dynamic obser-
vation during the test, on day 3 after the injection of APS, a
dense scarlet bleeding point appeared in the hypodermis,
and the subcutaneous petechia merged into flake and then
lasted for about 3e4 days. One week after the modeling,
hemorrhage was gradually relieved, and the blood color
gradually turned from scarlet to dark red, which was similar
to the manifestations of chronic hemorrhage in human ITP.
The bleeding degree of the three batches of mice is shown
in Figs. 1e3.
Coagulation time
After tests, a drop of eye ball blood was taken and put into
a vessel, and then disturbed with a syringe needle until
blood streak appeared. The lasting time (second) was
recorded. The results of coagulation time of the three test
batches are shown in Table 2.Figure 2 The second experiment showed bleeding in the ear.
Figure 3 The third experiment showed bleeding in toes, and
swelling.
Table 2 Change in coagulation time ðx  sÞ.
Test batch Coagulation time (s)
Normal group (n) Control group (n)
1st test batch 62.66  6.71 (12) 90.81  8.70* (11)
2nd test batch 61.60  2.88 (10) 81.90  4.12* (10)
3rd test batch 61.60  2.88 (10) 81.90  4.12* (10)
Note: *P < .01, as compared with that in the normal group.
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the coagulation time of model mice rose, which was sta-
tistically significant compared with those in the normal
group of the same test batch (P < .01).
Change in the type of medullary megakaryocyte
After the tests the mice were sacrificed. The sternum
marrowwas taken andmixed well in 25 mL calf serum. Smear
samples were quickly prepared. Wright’s staining after air
dried. One hundred megakaryocytes were calculated in
order and classified (megakaryoblast, promegakaryocyte,
granular megakaryocyte and thrombocytogenous megakar-
yocyte) by a microscope (10 100). The results of medullary
megakaryocyte of the three test batches are shown in
Table 3.Table 3 Type of medullary megakaryocyte ðx  sÞ.
Test batch Group (n) Megakaryoblast Pro
1st test batch Normal group (12) 6.25  1.48 27.
Model group (11) 4.18  1.33 30.
2nd test batch Normal group (10) 28.90  5.22 6.3
Model group (10) 32.20  5.90 3.7
3rd test batch Normal group (10) 28.90  5.22 6.3
Model group (10) 32.20  5.90 3.7
Note: *P < .05, P < .01, P < .001, as compared with that in the normAs shown in Table 3, compared with those in the normal
group of the same test batch, the count of medullary
thrombocytogenous megakaryocyte in the model mice
dropped even more (P < .01), and the count of medullary
naked nucleus megakaryocyte in the model mice also
dropped in the 2nd and 3rd test batches (P < .01).Judgment of the syndrome model
Behavioral observation
In the normal group, there were flexible response, smooth
hair, voluntary activity, active food rooting and stripy stool.
In the model group, 1 week after the injection of APS, there
were low activity, delayed activity, poor appetite, decrease
in food/water intake and skin petechia/ecchymosis; and 2
weeks after the injection of APS, there were delayed
response and withered hair, which was exacerbated with
the modeling duration.
Weight
The results of mice weight of the 1st and 2nd test batches
in both groups are shown in Table 4.
Table 4 showed that after the modeling of the 1st, 2nd
and 3rd batches there was no difference of weight between
the two groups in the 1st week. But from the 2nd week, the
weight of the model group dropped obviously, and there
was statistical significance in comparison with the normal
group before modeling (P < .05).Judgment of the disease-syndrome combined
model
According to the above test results, besides the skin
spontaneous hemorrhage at the injected sites or other
parts, the mice model of ITP possessed the following
manifestations: decrease in peripheral platelet count,
increase in coagulation time, decrease in medullary
thrombocytogenous megakaryocyte, low activity, delayed
activity, poor appetite, loose stool, lusterless hair, skin
petechia, and weight loss. As judged according to the
differentiation criteria for disease-syndrome combined
model of ITP, the APS-injected animal model of ITP
replicated through the passive immune modeling method





41  5.05 58.16  5.02 8.16  2.25
63  4.50 60.00  3.66 5.18  1.83*
0  2.45 56.80  5.77 8.10  1.85
0  1.42 58.9  5.49 5.20  1.48
0  2.45 56.80  5.77 8.10  1.85
0  1.42 58.90  5.49 5.20  1.48
al group.
Table 4 Comparison of mice weight g; ðx  sÞ.
Test batch Group (n) Before the modeling 1 week after the modeling 2 weeks after the modeling
1st test batch Normal group (12) 18.63  2.33 18.95  1.14 21.17  1.81
Model group (11) 20.21  1.51 17.69  1.52 17.18  1.94*
2nd test batch Normal group (10) 20.10  0.74 21.30  0.82 21.80  0.79
Model group (10) 20.00  0.82 19.50  0.67 18.70  0.95*
3rd test batch Normal group (20) 24.030  2.52 23.35  2.16 21.00  1.38
Model group (20) 23.93  2.66 22.07  1.64 20.65  1.35*
Note: *P < .05, as compared with that in normal group and before the modeling.
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According to the severity of disease, ITP is classified into
acute ITP (AITP) and chronic ITP (CITP).4 Based on the
TCM theory and the clinical manifestations, AITP often
occurs in children, and is a syndrome of bleeding due to
blood-heat. With acute pathogenesis, serious thrombocy-
topenia and massive hemorrhage, the following emer-
gency measures are necessary to rapidly control the
illness of AITP: platelet transfusion, hemostasis, and
massive administration of adrenocortical hormone or im-
mune globulin. For CITP, there are two types of syndrome:
syndrome of failure of the spleen to control blood and
syndrome of static blood blocking collateral.5 In the long
course of medical practice we have found traditional
Chinese medicine is the most effective to CITP because it
can relieve symptoms and bleeding, and improve periph-
eral platelet count.6 But we still have to confirm whether
a set of medicinal herbs used according to the theory of
traditional Chinese medicine is effective and what the
mechanism is. It is necessary to establish a disease-
syndrome combined animal model of good stability and
reproducibility, which can simulate the pathogenesis and
clinical characteristics of human ITP. However, as
analyzed by the existing literature, there is only the dis-
ease model of ITP, but no disease-syndrome combined
model of ITP.7 In order to verify this assumption, we
established the differentiation criteria for disease-
syndrome combined model of ITP according to the path-
ogenic and clinical characteristics of human ITP,
analyzed/summarized the three batches of data related
to the ITP model mice replicated through the passive
immune modeling method, and judged whether this
combined model conformed to the pathogenesis/syn-
drome characteristics of human ITP. We believe that it
may provide reference to treatment of ITP with rein-
forcing spleen qi to control blood. As shown by the test
results, the replicated APS-injected mice model of ITP
possessed the following characteristics: (1) Decrease in
platelet count, prolonging in coagulation time which had
statistically significance compared with those in the
normal group of the same test batch (P < .01). (2)
Decrease in medullary thrombocytogenous megakaryo-
cyte, which was statistically significant compared with
those in the normal group of the same test batch (P < .05,
.01, .001). (3) Spontaneous hemorrhage at the APS in-
jection site or other skin of model mice. (4) One week
after the modeling, there were low activity, delayedactivity, poor appetite, decrease in food/water intake,
loose stool, skin petechia/hemorrhage and spontaneous
hemorrhage at the injected sites or other parts and were
getting more and more severe. Therefore, according to
the differentiation criteria for the disease-syndrome
combined model of ITP, the APS-injected mice model of
ITP replicated through the passive immune modeling
method possessed the similar pathogenesis/syndrome
characteristics of human ITP.
The APS-injected mouse model of ITP replicated through
the passive immune modeling method featured various
advantages, e.g. high technological maturity, simple oper-
ation, good reproducibility, few interfering factors and
lower cost.8,9 However, the establishment of the disease-
syndrome combined animal model of ITP without addi-
tional conditions is still under exploration. In the past, we
attempted to establish a disease-syndrome combined ani-
mal model of ITP with the syndrome of blood stasis due to
qi deficiency, whose accuracy should still be further eval-
uated due to difficult selection of blood stasis indices and
insufficient evidence of blood stasis.10 This study specified
both the indices for the disease model of ITP and the
indices for syndrome transformation. As verified by sum-
marizing and analyzing the various test data according to
the differentiation criteria for the disease-syndrome com-
bined model, the objective indices for the APS-injected
mouse model of ITP replicated through the passive im-
mune modeling method not only conformed to the patho-
genesis characteristics of human ITP, but also the external
signs of TCM syndrome for this model were highly corre-
lated to human ITP, which proves that the disease-
syndrome combined animal model similar to the patho-
genesis of human ITP could be replicated without additional
conditions. Meanwhile, as shown by analyzing the contin-
uous dynamic observation results during the test, on Day 3
after injection of APS, a dense scarlet bleeding point
appeared on the hypodermis and injection site on the
model mice, the subcutaneous petechia merged into flake;
and the hemorrhage gradually turned from light-red to
dark-red about 3e4 days later. During such transient
change, the model mice still had the following obvious
signs: low activity, delayed activity, poor appetite,
decrease in food/water intake, weight loss and decrease in
swimming duration. This phenomenon could not be ratio-
nally explained as the syndrome of bleeding due to blood-
heat, and should be analyzed through further tests.
According to above results and conclusion, the following
issues might require further discussion and improvement.
140 H. Lang et al.(1) There is no generally-accepted differentiation criteria
for the disease-syndrome combined animal model of ITP,
thus the accuracy of diagnostic criteria for syndromes in
this study still requires further modification and improve-
ment. (2) APS is an exogenous antibody, and does not
originate from the study subject. After withdrawal of APS,
the low level of peripheral platelet count maintains for a
shorter time in the model mice, thus requiring further tests
to verify whether this model is the best for preventive
medication.7 (3) Although every index in this study has the
positive results (e.g. decrease in peripheral platelet count,
decrease in medullary thrombocytogenous megakaryocyte
and hemorrhage of various degrees) and possesses the
similar clinical syndrome/manifestations of human ITP,
more test evidences should still be required to determine
whether other modeling methods possess the above char-
acteristics.11,12 (4) Further studies are still needed to verify
the clinical significance and expression of platelet mem-
brane glycoprotein IIa/IIIb in this model (as the most con-
vincible anti-platelet antibody). Therefore, in future
studies, the animal model of ITP should be replicated in the
larger animal (i.e. guinea-pig or rabbit), so as to ensure a
sufficient blood specimen for index determination.
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